(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries...
Stats | |
---|---|
Šios dienos apimtis | 484 448 |
Vidutinė apimtis | 5.20M |
Rinkos kapitalizacija | 12.68M |
EPS | $0 ( 2024-02-27 ) |
Kita pelno data | ( $0 ) 2024-05-30 |
Last Dividend | $0.00878 ( 1997-05-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Tūris Koreliacija
Avecho Biotechnology Ltd Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Avecho Biotechnology Ltd Koreliacija - Valiuta/Žaliavos
Avecho Biotechnology Ltd Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $473 551 |
Bruto pelnas: | $-222 490 (-46.98 %) |
EPS: | $-0.00150 |
FY | 2023 |
Pajamos: | $473 551 |
Bruto pelnas: | $-222 490 (-46.98 %) |
EPS: | $-0.00150 |
FY | 2022 |
Pajamos: | $1.13M |
Bruto pelnas: | $793 118 (70.23 %) |
EPS: | $-0.00130 |
FY | 2021 |
Pajamos: | $1.06M |
Bruto pelnas: | $677 486 (63.94 %) |
EPS: | $-0.00324 |
Financial Reports:
No articles found.
Avecho Biotechnology Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00878 | 1997-05-19 |
Last Dividend | $0.00878 | 1997-05-19 |
Next Dividend | $0 | N/A |
Payout Date | 1997-06-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.00878 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TPG.AX | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
CYC.AX | Ex Dividend Junior | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
NUF.AX | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
FMG.AX | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% | |
PSQ.AX | Ex Dividend Junior | 2023-09-21 | Annually | 0 | 0.00% | |
ASX.AX | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
IGO.AX | Ex Dividend Knight | 2023-09-13 | Annually | 0 | 0.00% | |
SGM.AX | Ex Dividend Junior | 2023-10-03 | Annually | 0 | 0.00% | |
CDA.AX | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
MFG.AX | Ex Dividend Knight | 2023-08-23 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -7.26 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.470 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.802 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 8.30 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.83 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.53 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0239 | -1.500 | 9.60 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -298.85 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000334 | -0.000669 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000502 | -0.00100 | [0 - 20] |
debtEquityRatioTTM | 0.0275 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.470 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.69 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -18.16 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0647 | 0.800 | -2.90 | -2.32 | [0.5 - 2] |
Total Score | -2.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.69 | 1.000 | -0.474 | 0 | [1 - 100] |
returnOnEquityTTM | -0.802 | 2.50 | -6.44 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000334 | -0.00100 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000334 | -0.000669 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.115 | 1.500 | -2.57 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -6.72 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.43 |
Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.